Try our beta test site
13 studies found for:    AT13387
Show Display Options
Rank Status Study
1 Completed A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: AT13387 and Imatinib
2 Active, not recruiting A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387;   Drug: Crizotinib
3 Completed AT13387 in Adults With Refractory Solid Tumors
Conditions: Solid Tumors;   Breast Cancer
Intervention: Drug: AT13387
4 Completed A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Condition: Prostate Cancer
Interventions: Drug: AT13387;   Drug: abiraterone acetate;   Drug: Prednisone
5 Withdrawn Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Estrogen Receptor Negative;   Fallopian Tube Serous Neoplasm;   HER2/Neu Negative;   Ovarian Serous Adenocarcinoma;   Ovarian Serous Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
6 Recruiting Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
Interventions: Drug: CDKI AT7519;   Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Other: Pharmacological Study
7 Recruiting Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Metastatic Malignant Solid Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Unresectable Solid Neoplasm
Interventions: Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Other: Pharmacological Study;   Drug: Trametinib
8 Active, not recruiting Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
Conditions: Human Papillomavirus Infection;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Other: Pharmacological Study
9 Completed Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
Condition: Metastatic Solid Tumors
Intervention: Drug: AT13387
10 Not yet recruiting Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Malignant Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Onalespib;   Other: Pharmacological Study
11 Recruiting Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Other: Pharmacological Study
12 Recruiting AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   BCL6 Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Onalespib
13 Recruiting Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Onalespib;   Drug: Paclitaxel;   Other: Pharmacological Study

Study has passed its completion date and status has not been verified in more than two years.